↓ Skip to main content

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study

Overview of attention for article published in Cardiovascular Diabetology, January 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Published in
Cardiovascular Diabetology, January 2015
DOI 10.1186/s12933-015-0178-3
Pubmed ID
Authors

Sanjoy K Paul, Kerenaftali Klein, David Maggs, Jennie H Best

Abstract

BackgroundTo evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM).MethodsWe conducted a retrospective longitudinal pharmaco-epidemiological study using large ambulatory care data to evaluate the risks of heart failure (HF), myocardial infarction (MI) and stroke in established T2DM patients who received a first prescription of exenatide twice daily (EBID) or insulin between June 2005 and May 2009, with follow-up data available until December 2012. Three treatment groups were: EBID with oral antidiabetes drugs (OADs) (EBID, n¿=¿2804), insulin with OADs (Insulin, n¿=¿28551), and those who changed medications between EBID and insulin or had combination of EBID and insulin during follow-up, along with OADs (EBID¿+¿insulin, n¿=¿7870).Multivariate Cox-regression models were used to evaluate the association of treatment groups with the risks of macrovascular events.ResultsDuring a median 3.5 years of follow-up, cardiovascular event rates per 1000 person-years were significantly lower for the EBID and EBID¿+¿insulin groups compared to the insulin group (HF: 4.4 and 6.1 vs. 17.9; MI: 1.1 and 1.2 vs. 2.5; stroke: 2.4 and 1.8 vs. 6.1). Patients in the EBID / EBID¿+¿insulin group had significantly reduced risk of HF, MI and stroke by 61 / 56%, 50 / 38% and 52 / 63% respectively, compared to patients in the insulin group (p¿<¿0.01).ConclusionsTreatment with exenatide, with or without concomitant insulin was associated with reduced macrovascular risks compared to insulin; although inherent potential bias in epidemiological studies should be considered.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Spain 1 1%
Unknown 79 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 16%
Student > Bachelor 13 16%
Student > Master 11 14%
Researcher 8 10%
Other 5 6%
Other 16 20%
Unknown 15 19%
Readers by discipline Count As %
Medicine and Dentistry 34 42%
Agricultural and Biological Sciences 5 6%
Nursing and Health Professions 5 6%
Computer Science 3 4%
Biochemistry, Genetics and Molecular Biology 2 2%
Other 10 12%
Unknown 22 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2015.
All research outputs
#8,427,513
of 25,374,917 outputs
Outputs from Cardiovascular Diabetology
#659
of 1,653 outputs
Outputs of similar age
#110,203
of 359,728 outputs
Outputs of similar age from Cardiovascular Diabetology
#6
of 14 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 1,653 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,728 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.